-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 U1V1QG1lQC/eRYnVz05yH9SjYUGHwN++VndPKWvRkkuiFs4JtwPErkqYbpynsbBn
 WE9HLs7wIwWPnSmgHSNNnw==

<SEC-DOCUMENT>0001144204-10-033215.txt : 20100611
<SEC-HEADER>0001144204-10-033215.hdr.sgml : 20100611
<ACCEPTANCE-DATETIME>20100611214620
ACCESSION NUMBER:		0001144204-10-033215
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20100609
FILED AS OF DATE:		20100611
DATE AS OF CHANGE:		20100611

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Zhang Jian M
		CENTRAL INDEX KEY:			0001399061

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33650
		FILM NUMBER:		10893632

	MAIL ADDRESS:	
		STREET 1:		SUITE 602, CHINA LIFE TOWER
		STREET 2:		NO.16 CHAOWAI STREET, CHAOYANG DISTRICT
		CITY:			BEIJING
		STATE:			F4
		ZIP:			100020

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NeoStem, Inc.
		CENTRAL INDEX KEY:			0000320017
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090]
		IRS NUMBER:				222343568
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		420 LEXINGTON AVENUE
		STREET 2:		SUITE 450
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10170
		BUSINESS PHONE:		212-584-4171

	MAIL ADDRESS:	
		STREET 1:		420 LEXINGTON AVENUE
		STREET 2:		SUITE 450
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10170

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PHASE III MEDICAL INC/DE
		DATE OF NAME CHANGE:	20030819

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CORNICHE GROUP INC /DE
		DATE OF NAME CHANGE:	19951117

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	FIDELITY MEDICAL INC
		DATE OF NAME CHANGE:	19951025
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>v188051_ex.xml
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0303</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2010-06-09</periodOfReport>

    <notSubjectToSection16>0</notSubjectToSection16>

    <issuer>
        <issuerCik>0000320017</issuerCik>
        <issuerName>NeoStem, Inc.</issuerName>
        <issuerTradingSymbol>NBS</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001399061</rptOwnerCik>
            <rptOwnerName>Zhang Jian M</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>859 PANXU ROAD</rptOwnerStreet1>
            <rptOwnerStreet2>CANGLANG DISTRICT</rptOwnerStreet2>
            <rptOwnerCity>SUZHOU CITY, JIANGSU PROVINCE</rptOwnerCity>
            <rptOwnerState>F4</rptOwnerState>
            <rptOwnerZipCode>215002</rptOwnerZipCode>
            <rptOwnerStateDescription>CHINA</rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>0</isDirector>
            <isOfficer>1</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle>See Remarks</officerTitle>
        </reportingOwnerRelationship>
    </reportingOwner>

    <derivativeTable>
        <derivativeTransaction>
            <securityTitle>
                <value>Warrants (right to buy)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>2.16</value>
            </conversionOrExercisePrice>
            <transactionDate>
                <value>2010-06-09</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>A</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>650000</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>0</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <exerciseDate>
                <footnoteId id="F1"/>
            </exerciseDate>
            <expirationDate>
                <value>2020-06-08</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock, par value $0.001 per share</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>650000</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>650000</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeTransaction>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">On June 9, 2010 (the &quot;Grant Date&quot;), the reporting person was granted a warrant to purchase 650,000 shares of common stock of
 NeoStem, Inc. (the &quot;Company&quot;) pursuant and subject to the terms and conditions of the Company's 2009 Non-U.S. Based Equity
 Compensation Plan. This warrant vested as to 150,000 shares on the Grant Date, and is scheduled to vest (i) as to 50,000
 shares on each of the first, second, third, fourth and fifth anniversaries of the Grant Date and (ii) as to 250,000 shares
 upon the achievement of specific business milestones.</footnote>
    </footnotes>

    <remarks>Vice President, Pharmaceutical Operations, and General Manager of Suzhou Erye Pharmaceuticals Company Ltd., a 51% owned
 subsidiary of the Company.</remarks>

    <ownerSignature>
        <signatureName>Jian Zhang, By: /s/ Catherine M. Vaczy, Esq., Attorney-in-Fact</signatureName>
        <signatureDate>2010-06-11</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----